A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Valspodar (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.